STENTYS announced the one-year results of the APPOSITION III clinical trial in 1,000 patients post treatment of a severe heart attack. The APPOSITION III trial, a prospective, single-arm, multi-center study, was designed to assess the long term performance of STENTYS Self-Apposing Stents in routine clinical practice in Europe among patients suffering from ST-elevation myocardial infarction. The very low rates of mortality and target-vessel re-infarction in the study highlighted the safety profile of Self-Apposing stents. The company said the strong results continue to suggest the superiority of the Self-Apposing Stent in the treatment of AMI.
STENTYS expects the data will contribute to the ongoing adoption of the technology among cardiologists in Europe and further support the initiation of the company’s FDA-approved U.S. pivotal trial, APPOSITION V, during the first half of 2013.
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News